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Effect of dietary management on the gastric endocrine
cells in patients with irritable bowel syndrome
T Mazzawi1,2, T Hausken2, D Gundersen3 and M El-Salhy1,2
BACKGROUND/OBJECTIVES: The gastric endocrine cells in patients with irritable bowel syndrome (IBS) tend to normalize
following dietary guidance. The aim of the present study was to identify the gastric endocrine cell types that are changed following
such dietary guidance.
SUBJECTS/METHODS: Fourteen IBS patients and 14 healthy subjects were included in the study. Patients received three sessions of
individual dietary management guidance. Gastroscopy was performed on both the controls and the patients at baseline and then
again for the patients at 3–9 months after dietary guidance. Biopsy samples from the corpus and antrum were immunostained for
all gastric endocrine cell types. Endocrine cells were quantiﬁed by computerized image analysis.
RESULTS: The densities of the ghrelin cells for the controls and IBS patients before and after dietary guidance were 149.6 ± 36.2
(mean± s.e.m.; 95% conﬁdence interval (CI) 71.3–227.8), 114.5 ± 32.7 and 161.8 ± 37.8 cells/mm2, respectively. The densities of the
gastrin cells in these groups were 155.8 ± 21.0 (95% CI 110.3–201.2), 159.4 ± 24.3 and 211.6 ± 28.0 cells/mm2, respectively; the
corresponding densities of serotonin cells in the corpus were 18.2 ± 3.9 (95% CI 9.8–26.6), 10.6 ± 3.4 and 14 ± 2.0 cells/mm2 and in
the antrum were 44.6 ± 12.2 (95% CI 18.1–71.1), 1.7 ± 0.5 and 14.7 ± 6.3 cells/mm2. The densities of the somatostatin cells in the
corpus were 40.0 ± 7.7 (95% CI 23.5–56.5), 23.0 ± 3.0 and 37.3 ± 4.2 cells/mm2, respectively, and in the antrum were 138.9 ± 22.0
(95% CI 91.4–186.3), 95.6 ± 15.9 and 86.0 ± 16.9 cells/mm2, respectively.
CONCLUSIONS: The densities of all of the gastric endocrine cell types changed towards the healthy control values in the IBS
patients following a change in food intake.
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INTRODUCTION
The gastrointestinal endocrine cells regulate several functions of
the gut such as sensation, motility, secretion, absorption, local
immune defence and food intake via controlling the appetite.1,2
These cells have specialized microvilli that project into the gut
lumen and act as sensors for the luminal contents, mainly
nutrients, and respond to luminal stimuli by releasing hormones
that generally target other parts of the digestive system.1,2
Abnormalities in the gastrointestinal cells have been reported in
patients with irritable bowel syndrome (IBS), and it has been
suggested that this abnormality has a major role in the
pathophysiology of IBS.1,2 It has also been demonstrated that
the gastric endocrine cells are abnormal in IBS patients, and the
conclusion has been drawn that the pathophysiology of IBS is not
restricted to the large intestine.1–4
A previous study performed by our group found that a change
in food intake in IBS patients established by dietary guidance
reduced the symptoms and improved the quality of life in these
patients.5 Investigation of the total gastric endocrine cell
population, as revealed by chromogranin A staining, revealed
that in the same patient cohort the density of gastric endocrine
cells tended to normalize following dietary guidance.6 The aim of
the present study was to identify which gastric endocrine cell
types were affected by a change in food intake in that same
cohort of IBS patients.5,6
MATERIALS AND METHODS
Patients and controls
The inclusion criteria for this study were that patients fulﬁlled Rome-III
criteria for IBS diagnosis and were aged 18–70 years. The following exclusion
criteria were applied: women who were pregnant or lactating, or who had a
Caesarean section or hysterectomy, and patients with organic gastrointest-
inal or other systemic diseases, drug abuse, serious psychiatric disturbances
or previous abdominal surgery (with the exception of appendectomy). Eight
patients did not consume any kind of medications. Six patients used one or
a combination of the following: proton pump inhibitors (n=4), anti-
hypertensive Losartan (n=1), anti-allergic medications (n=3), contraceptive
pills (n=2), thyroxin substitution tablet (n=2), asthma inhalator medications
(n=1), and anti-depressants/anxiolytics (n=2). These patients were told not
to take any kind proton pump inhibitors during the study.
Patients who underwent gastroscopy to investigate gastrointestinal
bleeding, where the source of bleeding was identiﬁed as haemorrhoids
(n=3) or angiodysplasia (n=1) or because of health worries in healthy
subjects due to family member(s) having been diagnosed with gastro-
intestinal cancer (n=10) were used as controls. The control group comprised
nine females and ﬁve males with a mean age of 54 years (range 26–70 years).
The study was performed in accordance with the Declaration of Helsinki
and approved by the local Committee for Medical Research Ethics, West,
Bergen, Norway. All patients submitted both oral and written consent to
participate.
Study design
A total of 46 patients were recruited to the study. They were 35 females
and 11 males with a mean age of 35 years (range 18–69 years).
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Patients were examined physically, and blood tests were taken to exclude
inﬂammation, infection or other organic disease. These patients also
underwent colonoscopy with segmental biopsy sampling to exclude
microscopic colitis. Each patient was scheduled for three sessions of
individual dietary management guidance of about 45min, each with a
nurse with education and long experience in dietary guidance in IBS. These
sessions were timed at intervals of at least 2 weeks. The patients
underwent gastroscopy, before the ﬁrst session and 3–9 months (median
4 months) following the third dietary management guidance session.
Individual dietary management guidance
The information was delivered orally with the help of charts, as well as
written illustrated information. The ﬁrst session included general informa-
tion about IBS and the importance of regular and healthy eating habits, the
diets that worsen IBS symptoms, such as insoluble dietary ﬁbre and
FODMAPs (the poorly absorbed highly fermentable oligosaccharides,
disaccharides, monosaccharides and polyols). The patients were encour-
aged to consume dairy products daily and were informed that milk and
dairy products do not provoke IBS symptoms. The patients were required
to keep a diary for 2 weeks, in which they registered their daily food and
drink intake as well as the frequency and degree of abdominal pain,
abdominal distension and stool frequency and consistency. In addition, the
patients were asked to test a protein-, fat- or carbohydrate-rich/poor diet.
The patients were also instructed to avoid the intake of food items
supplemented with probiotics, antibiotics and other medications (if not
otherwise advised) during the course of the study. In the second session,
the information given at the ﬁrst session was brieﬂy repeated. The nurse
and the patient determined the symptom-triggering items based on the
information noted in the patient’s diary. The patients were then advised to
alter the proportions of protein, fat and carbohydrate, avoid items rich in
FODMAPs and insoluble ﬁbre, as well as consume vegetables and fruits
containing less FODMAPs and insoluble ﬁbre. During the ﬁnal session,
patients described their experience of dietary management to the nurse.
The nurse and patient then together designed a suitable diet for the
patient, who followed it strictly until the end point of the study.
Dietary assessment
Dietary intake was assessed using a semi-quantitative, self-administered
food frequency questionnaire (MoBa food frequency questionnaire). The
questionnaire reported the frequency of consumption and portion size of a
series of foods and beverages over a deﬁned period of time. The data were
then analysed by software for nutrient calculations. The MoBa food
frequency questionnaire used in the current study was developed and
validated by the Norwegian Institute of Public Health in Oslo, Norway.7,8
It enquires about the intake of 225 food items and captures the dietary
habits of the participant, including the intake of any oral supplements,
according to typical Norwegian meal patterns. The participants received
two sets of MoBa food frequency questionnaire, which were ﬁlled out and
delivered before and at least 3 months after dietary management
guidance.9
Gastroscopy, tissue sampling, histopathology and
immunohistochemistry
After an overnight fast, patients and control subjects underwent standard
gastroscopy. Four biopsy samples were taken from the corpus (major
curvature) and another four biopsy samples from the antrum of the
stomach. A further four biopsy samples were taken from the duodenum to
exclude coeliac disease.
The biopsy samples were ﬁxed in 4% buffered paraformaldehyde
overnight, embedded in parafﬁn wax and then cut into
5-μm-thick sections. Biopsy samples from the stomach and duodenum
were examined histopathologically. Biopsy samples from the corpus and
antrum were stained with haematoxylin–eosin and immunostained using
the avidin–biotin complex method using the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) and the 3,3′-diaminobenzidine
peroxidase substrate kit (Vector Laboratories) as described previously.10
Brieﬂy, the sections were incubated for 2 h at room temperature with a
primary antibody/antiserum, after which they were washed in phosphate-
buffered saline (pH 7.4) and incubated for 30min at room temperature
with biotinylated swine antimouse immunoglobulin G diluted to 1:200. The
slides were washed with phosphate-buffered saline and then incubated
for 30min with avidin–biotin–peroxidase complex diluted to 1:100.
The slides were again washed with phosphate-buffered saline, submerged
in 3,3′-diaminobenzidine peroxidase substrate and then counterstained
with haematoxylin–eosin. The primary antibodies/antisera used were
monoclonal mouse anti-N-terminal of human ghrelin (code 2016003,
Millipore, Temecula, CA, USA), monoclonal mouse antihuman serotonin
(clone 5HT-H209, code M0758, Dako, Glostrup, Denmark), polyclonal rabbit
antisynthetic, cyclic somatostatin (code A0566, Dako), monoclonal mouse
antihistamine (serotonin)-hexamethylene, diisocyanate-bovine serum albu-
min (code 2273835, Millipore, Darmstadt, Germany) and polyclonal rabbit
antihuman gastrin (code A0568, Dako).
Computerized image analysis
The densities of the various types of endocrine cells in the corpus and
antrum in patients with IBS and controls were evaluated using the
software Cell ^D (Olympus, Tokyo, Japan). The number of endocrine cells
and the area of epithelial cells were measured in 10 randomly chosen
ﬁelds, at a magniﬁcation of × 40, for which each ﬁeld represented a
tissue area of 0.14 mm2. The endocrine cell density is expressed as the
number of cells per square millimetre of epithelium. Quantiﬁcation was
conducted by the same person (TM), who was blinded to the identity of
the sections.
Statistical analysis
The paired t-test was used to compare patients before and after dietary
guidance and healthy controls. The data are presented as mean± s.e.m.
values. The cutoff for statistical signiﬁcance was set at Po0.05.
RESULTS
Patients and controls
Twenty-ﬁve patients withdrew their consent, 2 before and 23 after
receiving dietary guidance and with consequent improvement in
their symptoms. Two patients were excluded because of non-
compliance, two because they were diagnosed with coeliac
disease and one who had been diagnosed with lupus. In addition,
two patients were excluded because of pregnancy during the
study and moving abroad. Thus, 14 of the initial 46 patients
completed the entire study. These patients comprised 9 females
and 5 males with a mean age of 34 years (range 20–45 years).
Biopsy samples were not obtained from the corpus of one of the
female patients.
Dietary assessment
The daily total consumption (mean± s.e.m.) of FODMAP-rich fruits
and vegetables decreased signiﬁcantly after dietary guidance
compared with before receiving dietary guidance (9.2 ± 3.2,
16.2 ± 5.3 g, respectively, P= 0.016).9 The daily consumption of
ﬁbre (mean± s.e.m.) before and after dietary guidance were
27.4 ± 2.5 and 23.1 ± 2.2 g, respectively, (P= 0.093).9
Gastroscopy, histopathology and immunohistochemistry
Endoscopy of the upper oesophagus, stomach and duodenum
revealed a normal appearance, and histopathological examina-
tions of the stomach and duodenum revealed a normal structure.
Serotonin- and somatostatin-immunoreactive cells were found in
the mucosa of both the corpus and antrum in the patients and
controls. Whereas ghrelin-positive cells were found exclusively in
the oxyntic mucosa of the corpus, gastrin-positive cells were
found only in the antrum. The number of histamine-
immunoreactive cells in the biopsy samples used in the study
was low and did not allow reliable quantiﬁcation.
Computerized image analyses
Ghrelin. In the control group, the density of ghrelin cells in the
gastric corpus was 149.6 ± 36.2 cells/mm2 (95% conﬁdence
interval (CI) 71.3–227.8). The density of ghrelin cells in the IBS
patients did not differ signiﬁcantly between before (114.5 ± 32.7
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cells/mm2) and after (161.8 ± 37.8 cells/mm2) receiving dietary
guidance (P= 0.09, paired t-test; Figures 1 and 2).
Gastrin. The densities of the gastrin cells in the antrum were
155.8 ± 21.0 (95% CI 110.3–201.2), 159.4 ± 24.3 and 211.6 ± 28.0
cells/mm2 in the controls and in the IBS patients before and after
dietary guidance, respectively (Figure 3). The cell density did not
differ signiﬁcantly between before and after dietary guidance in
the IBS patients (P= 0.26).
Serotonin. In the corpus, the density of serotonin cells in the
control group was 18.2 ± 3.9 cells/mm2 (95% CI 9.8, 26.6), while
those in IBS patients before and after receiving dietary
guidance were 10.6 ± 3.4 and 14.0 ± 2.0 cells/mm2, respectively
(Figure 4). The cell density did not differ signiﬁcantly between
before and after dietary guidance (P = 0.4). In the antrum,
the corresponding values were 44.6 ± 12.2 cells/mm2 (95% CI
18.1–71.1), 1.7 ± 0.5 and 14.7 ± 6.3 cells/mm2, respectively.
There was no signiﬁcant difference between the ﬁndings
before and after dietary guidance in the IBS patients
(P = 0.06).
Somatostatin. In the control group, the densities of somatostatin
cells in the corpus and antrum were 40.0 ± 7.7 cells/mm2
(95% CI 23.5–56.5) and 138.9 ± 22.0 cells/mm2 (95% CI 91.4–186.3),
respectively. The somatostatin cell density in the antrum in the IBS
patients did not differ signiﬁcantly between before and after
receiving dietary guidance (95.6 ± 15.9 and 86±16.9 cells/mm2,
respectively; P=0.6). However, the cell density was signiﬁcantly
higher in the corpus compared with before the intervention
(23.0 ± 3.0 and 37.3± 4.2 cells/mm2, respectively; P=0.02; Figures 5
and 6).
DISCUSSION
Studies of IBS patients have experienced high dropout rates,
ranging from 44% to 48%.11,12 The dropout rate in the present
study was also high, at 54%, which may be explained by the
design of the study, which was demanding, involving two
invasive examinations (gastroscopy) and the expectation that the
patient follow the recommended diet strictly for at least
3 months. It is noteworthy that the dropouts occurred mostly
after receiving dietary guidance and the associated improve-
ments in the patients’ symptoms. There were also other factors
that decreased the number of IBS patients who completed this
study. Despite the small number of patients in the studied
sample, a clear change in the densities of all the gastric
endocrine cells occurred following changes in the food intake
in the IBS patients towards the values measured for the healthy
control subjects.
Figure 2. Ghrelin-immunoreactive cells in the oxyntic mucosa in a
control (a) and in an IBS patient before (b) and after (c) receiving
dietary guidance.
Figure 1. Ghrelin cell density in the oxyntic mucosa in controls and
in IBS patients before and after receiving dietary guidance. The
dashed lines labelled ‘a’ and ‘c’ show the upper and lower limits of
the 95% CI in healthy controls, respectively, while line ‘b’ shows the
mean ghrelin cell density.
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The endocrine cells in the oxyntic mucosa of the stomach are
the main source of ghrelin in the body. Ghrelin has several
functions, including the release of growth hormone and
regulating appetite and energy metabolism.13–16 Furthermore,
ghrelin accelerates gastric and small- and large-intestinal
motility and stimulates the secretion of gastric acid.17–28
Serotonin stimulates large-intestinal motility and accelerates
transit through the small and large intestines.29–37 It also
activates the submucosal sensory branch of the enteric nerve,
which conveys sensation from the gut to the central nervous
system.29,33–35 Somatostatin inhibits intestinal contraction and
gastrointestinal exocrine and endocrine secretion.38,39 Finally,
gastrin is the main hormonal stimulant of acid secretion in the
stomach.40–44 Given the collective functions of these four types
of gastric endocrine cells, it is possible to speculate that the
changes in the densities of these cells towards normal levels
following a change in food intake are responsible for the
simultaneous improvements in IBS symptoms associated with
disturbed gut motility, visceral hypersensitivity and abnormal
gastrointestinal secretion.
The gut luminal contents, and especially the nutrients, are the
main stimuli that trigger gut endocrine cells' activity.1,2 Stem cells
rapidly differentiate into endocrine cells in the gut, over a period
of just a few days.42,43 It is tempting to speculate that the change
in diet and the consequent change in the contents of the gut
lumen are responsible for the changes in the gastric endocrine
cells observed here. If this assumption is proven to be true, this
Figure 5. Somatostatin cell density in the oxyntic mucosa (a) and the
antrum (b) in controls and in IBS patients before and after receiving
dietary guidance. The symbols are the same as in Figure 1. *Po0.05.
Figure 4. Serotonin cell density in the oxyntic mucosa (a) and the
antrum (b) in controls and in IBS patients before and after receiving
dietary guidance. The symbols are the same as in Figure 1.
Figure 3. Gastrin cell density in the antrum in controls and in IBS
patients before and after receiving dietary guidance. The symbols
are the same as in Figure 1.
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would open new frontiers with important clinical implications for
IBS patients.
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